

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
Form 10-K
March 19, 2003

=====

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-K

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 31, 2002
(For the fiscal year ended)

1-9731
(Commission file number)

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation of organization)

72-0925679
(IRS Employer Identification Number)

25 Sawyer Passway, Fitchburg, MA
(Address of principal executive offices)

01420
(Zip Code)

(978) 345-5000
(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12 (b) of the Act:

Common Stock, \$.01 par value
(Title of Each Class)

American Stock Exchange
(Name of Each Exchange on Which Registered)

Securities Registered Pursuant to Section 12 (g) of the Act:

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes No

On February 21, 2003 there were 2,717,076 shares of the registrant's common stock outstanding, par value \$.01, which is the only class of common or voting stock of the registrant. As of June 30, 2002, the aggregate market value of the voting stock of the registrant held by non-affiliates was \$6,737,525 based upon the closing price of the shares of common stock on the American Stock Exchange.

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2002. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K.

=====

Arrhythmia Research Technology, Inc. Table of Contents

Part I	Item 1	Business
	Item 2	Properties
	Item 3	Legal Proceedings
	Item 4	Submission of Matters to a Vote of Security Holders
Part II	Item 5	Market for Registrant's Common Equity and Related Stockholder Matters
	Item 6	Selected Financial Data
	Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operations
	Item 7A	Quantification and Qualitative Disclosures about Market Risk
	Item 8	Financial Statements and Supplementary Data
	Item 9	Change in and Disagreements with Accountants on Accounting and Financial Disclosure
Part III	Item 10	Directors and Executive Officers of the Registrant
	Item 11	Executive Compensation
	Item 12	Security Ownership of Certain Beneficial Owners and Management
	Item 13	Certain Relationships and Related Transactions
	Item 14	Controls and Procedures
Part IV	Item 15	Exhibits, Financial Statements Schedules, and Reports on Form 8-K
Schedule II		Signatures
		Valuation and Qualifying Accounts

PART I

Item 1. BUSINESS

OVERVIEW

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Arrhythmia Research Technology, Inc. ("ART" or the "Company") was incorporated under the laws of the State of Louisiana in 1981 and reincorporated under the laws of the State of Delaware in 1987. ART is engaged in the sales and licensing of medical software, which acquires data and analyzes electrical impulses of the heart to detect and aid in the treatment of potentially lethal arrhythmias. ART's products consist of signal-averaging electrocardiographic (SAECG) software. ART recently completed an update to a Windows based version of its proprietary Predictor(R) series. Rather than restore a direct sales force, the Company's intent is to market ART's product through licensing with original equipment manufacturers. No significant sales of these units were recorded in 2002 and 2001 nor are currently forecasted for the year 2003. Work continues to establish contracts with original equipment manufacturers for this product.

Sudden cardiac death afflicts over 400,000 individuals in the United States each year. These occurrences are due to sustained ventricular tachycardia (abnormally rapid heartbeat) or ventricular fibrillation (very fast, completely irregular heartbeat), which severely affect the capability of the heart's pumping chambers or ventricles. The electric signals that emanate from the heart are used to detect the presence of late potentials, which indicate the risk of life threatening ventricular arrhythmias. The SAECG processes enable late potentials to be amplified and enhanced, while eliminating undesired electrical noise in these crucial tests.

ART's wholly owned subsidiary, Micron Products, Inc. ("Micron"), is a manufacturer and distributor of silver plated and non-silver plated conductive resin sensors ("sensors") used in the manufacture of disposable electrodes constituting a part of ECG diagnostic and monitoring instruments. Micron also acts as a distributor of metal snap fasteners ("snaps"), another component used in the manufacture of disposable electrodes. In 1997, Micron acquired the rights to an assembly machine, which it now manufactures and sells or leases to its sensor and snap customers. Micron was incorporated in the State of Massachusetts in 1972 and is located in Fitchburg, Massachusetts. The sensors are a critical component of the signal pathway in many different types of disposable electrodes. The disposable electrodes used to capture the electric impulses of the heart and enable the analysis of late potentials require sensors which provide for an accurate, low noise signal to be transmitted to the monitoring device.

Micron is the largest of a few companies providing silver / silver-chloride sensors to the medical device industry. Micron's customers manufacture monitoring and transmitting electrodes which are utilized in a variety of bio-feedback and bio-stimulation applications including, among many others, electrocardiograms (ECG's), electroencephalograms (EEG's), electro-muscular stimulation (EMS), and thermo-electrical neural stimulation (TENS).

PRODUCTS

The following table sets forth for the periods specified, the revenue derived from the products of ART and its subsidiary Micron (collectively the "Company"):

		2002	%	Period Ending December 31, 2001	%	2000
Sensors	\$	6,599,677	92	\$ 6,388,003	88	\$ 6,827,178
Snaps & Snap Machines ...		588,648	8	689,948	10	1,515,074
CardioLab & CardioMapp ..		-	-	-	-	1,000,000

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

SAECG products	3,740	-	141,737	2	114,823
Other	-	-	-	-	64,788
	-----		-----		-----
Total	\$ 7,192,065	100	\$ 7,219,688	100	\$ 9,521,863
	=====		=====		=====

3

Sensors and Snaps

Silver Plated Sensors

Micron is a manufacturer and distributor of silver-plated and non-silver plated conductive resin sensors for use in the manufacture of disposable electrodes for ECG diagnostic, monitoring and related instrumentation. The disposable electrode has proven to be more accurate and reliable than the reusable electrodes available in the market. Additionally, disposable electrodes are faster, easier, and less expensive to use as compared to reusable electrodes, which require sterilization after each use. The type of sensor manufactured by Micron consists of a molded plastic substrate plated with a silver/silver chloride surface, which is a highly sensitive conductor of electrical signals. Silver/silver chloride-plated disposable electrodes are utilized in coronary care units and for other monitoring purposes. In addition to the traditional ECG tests, disposable electrodes incorporating Micron's sensor are used in connection with stress tests and a "Holter" monitor.

Micron also manufactures sensors and conductive plastic studs used in the manufacture of radiotranslucent electrodes. The radiotranslucent electrodes are virtually invisible to X-rays and are preferred in some applications such as nuclear medicine, cath labs, ICU/CCU and certain stress and Holter procedures.

Metal Snap Fasteners

Metal snap fasteners are used to attach the disposable electrode to the lead wires of an ECG machine. Micron purchases the metal snap fasteners for resale from a supplier and performs additional quality control tests, repackaging and inventory stocking for its customers who can purchase the snaps along with Micron sensors.

High Speed Electrode Assembly Machine

Pursuant to a purchase agreement, dated March 5, 1997, Micron acquired from Newmark, Inc. substantially all its assets used in the business of manufacturing, leasing and selling medical sensor and snap application machines. Electrode assembly machines provide Micron with a complimentary product to sell to existing sensor and snap customers.

Signal-Averaging Electrocardiographic (SAECG) Products

Predictor(R) 7

Predictor(R) 7 consists of a Windows(R) compatible analytical software which produces a hard copy of the signal averaged test. Early Potential Analysis software has also been incorporated specifically for P wave-triggered SAECG analysis and is used as a research tool in assessing patients at risk for atrial fibrillation and flutter. The IntraSpect(TM) module permits visualization and quantification of electrical fragmentation within the entire QRS complex (entire ventricular depolarization cycle), using individual-lead Acceleration Spectrum

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Analysis (ASA). Hence, micropotential detection is no longer limited to the 'late potential' region. Furthermore, patients with conduction delay problems (i.e. "bundle branch block") can have SAECG analysis performed on them. The Early Potential Analysis software and the IntraSpect(TM) module are not approved by the FDA, and are for research purposes, not clinical diagnosis.

GENERAL

Customers and Sales

Micron manufactures its sensors against customer purchase orders with electrode manufacturers. There are approximately 30 significant manufacturers of disposable snap type and radio translucent electrodes worldwide. Micron sells its sensors to most of these manufacturers. During the year ended December 31, 2002, three major customers individually accounted for over 10% of Micron's sales and a loss of this base would have a material adverse effect on results. These customers account for 36%, 20% and 19% of sales. Sales backlog is not material to Micron's business due to the method of ordering employed by its customer base in this competitive industry. Customers purchase on a single purchase order basis without long-term commitments.

Windows(R) is a registered trademark of the Microsoft Corporation.

4

The following table sets forth, for the periods indicated, the approximate consolidated revenues and percentages of revenues derived from the sales of the Company's products in its geographic markets:

	Revenues for the Years Ended December 31			
	2002	%	2001	%
	-----	-----	-----	-----
United States	\$ 1,115,941	16	\$ 1,311,334	18
Europe	2,669,631	37	2,819,654	39
Canada	3,133,890	44	2,765,531	38
Pacific Rim	230,917	3	274,959	4
Other	41,686	-	48,210	1
	-----	-----	-----	-----
Subtotal	\$ 7,192,065	100	\$ 7,219,688	100
	=====	=====	=====	=====
GE/Prucka termination payment				
Total				\$
				==

While some risks exist in foreign markets, the vast majority of the Company's customers are based in stable markets. To reduce the risk of the foreign shipment and currency, the majority of our products are the responsibility of our customers when shipped, and payment is always required in US Dollars.

Marketing and Competition

Due to the efforts to concentrate on licensing ART SAECG products, the sales department has been consolidated to the Fitchburg office. From time to time the sales and marketing department employs outside consultants to penetrate

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

new markets. The expenditure for these consultants was \$7,500 and \$14,670 in 2002 and 2001.

Micron sells its sensors to manufacturers of disposable snap type and radio translucent ECG electrodes. The Company believes that it has one major domestic competitor and several minor competitors worldwide for sensors, and that its sales of sensors exceed those of its competition. The competition in the sensor and snap market is extremely price sensitive.

Product Suppliers and Manufacturing

Micron manufactures its sensors at its Fitchburg, Massachusetts facility employing a proprietary non-patented multi-step process. The raw materials used by Micron are (1) plastic resins used to mold the substrates and (2) silver/silver chloride chemical solutions for plating the molded plastic substrates. Both the resins and the chemical involved in the silver/silver chloride process are in adequate supply. Fluctuations in the price of silver are contractually passed to customers. All of the chemicals and resins used in any significant volume in the Micron sensor operations are commodities that are readily available from numerous regional suppliers.

Micron's distributes medical snap fasteners manufactured by Newmark, Inc. Micron buys the snaps in bulk, performs additional quality control tests, and stocks inventory for its customers.

Inventory Requirements

Our larger customers benefit from our ability to maintain inventory of standard sensors and snaps. This stocking inventory allows for predictable and planned production resulting in cost efficiencies that have been passed on to our customers.

Research and Development

ART's research and development efforts focused primarily on converting DOS software packages in the SAECG product lines into a Windows environment. For the fiscal years ended December 31, 2002, 2001, and 2000, ART had research and development expenses of approximately \$24,000, \$215,000, and \$229,000, respectively, which consisted principally of the salaries of its employees and programming consultants.

Micron spent \$28,000 in 2002 for research and development related to a new type of silver plated sensor in order to expand its volume primarily in the Pacific Rim region. Funding for further development is readily available, but is not expected to exceed the amount spent in 2002.

Patents and Proprietary Technology

The Simson Patent expired in 2002. This technology covers the signal averaging and filtering technologies utilized in the Predictor(R) 7 product. The Simson technology has been coupled to a patented process (Mortara) that is used by ART products and effectively extends the useful life of Simson technologies. ART believes that patent protection is important to its business and anticipates that it will apply for additional patents or extensions as deemed appropriate.

As part of the purchase of substantially all the assets of Corazonix in 1993, ART acquired three patents related to time and frequency domain analysis of electrocardiogram signals. ART acquired U.S. Patent No. 5,117,833 entitled

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

"Bi-Spectral Filtering of Electrocardiogram Signals to Determine Selected QRS Potentials," (the "Bi-Spec Patent") which expires in 2009. ART also acquired three additional patents, which cover the spectral-temporal, mapping post-processing software packages sold by ART. The U.S. Patent Office granted United States Patent No. 5,609,158 entitled "Apparatus and Method for Predicting Cardiac Arrhythmia, by Detection of Micropotentials and Analysis of all ECG Segments and Intervals" which covers a frequency domain analysis technique for SAECG data, in March 1997. The Corazonix technologies are also utilized in the current version of Predictor(R) 7.

The Company believes that ART's products do not and will not infringe on patents or violate proprietary rights of others. In the event that ART's products infringe patents or proprietary rights of others, ART may be required to modify the design of its products or obtain a license. There can be no assurance that ART will be able to do so in a timely manner upon acceptable terms and conditions. In addition, there can be no assurance that ART will have the financial or other resources necessary to enforce or defend a patent infringement or proprietary rights violation action. Moreover, if ART's products infringe patents or proprietary rights of others, ART could, under certain circumstances, become liable for damages, which could have a material adverse effect on earnings.

Micron employs a highly complex, proprietary non-patented multi-step manufacturing process for its silver/silver chloride-plated sensors. To maintain our trade secrets associated with the manufacture of disposable electrode sensors, key employees have executed nondisclosure and non-competition agreements.

Government Regulation

ART's software products are subject to and currently comply with clearance and distribution requirements from governmental regulatory authorities, principally the FDA and the EU. These agencies promulgate quality system requirements under which a medical device is to be developed, validated and manufactured. Continued development of the product line is managed in accordance with applicable regulatory requirements.

Micron's sensor elements are not considered medical devices. As such, they are not required to be listed with regulatory agencies and do not need to have regulatory clearance for distribution. However, because Micron primarily distributes sensors to manufacturers for use in finished medical devices, Micron exercises the same controls over their manufacturing processes and finished products as would be required if the sensors were considered medical devices.

Environmental Regulation

Micron's operations involve use of hazardous and toxic materials and generate hazardous, toxic and other wastes. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and certain waste products. Although we believe that our safety procedures for using, handling, storing and disposing of such materials comply with these standards required by state and federal laws and regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. A specific insurance policy has been purchased to offset this risk to the Company and the environment. A contingency reserve equal to two deductibles on the policy is on our balance sheet minimizing the potential to adversely impact future operating results.

Since its inception, Micron has expended significant funds to train its personnel, install waste treatment and recovery equipment and to retain an independent environmental consulting firm to constantly review, monitor and upgrade its air and waste water treatment activities. In 2002, the related

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

expenditures for waste treatment were approximately \$40,000 and \$48,000 in depreciation of the treatment equipment. Operational costs are expected to

6

be similar in 2003, while scheduled depreciation expense decreases to \$4,500. As a result, Micron believes that the operation of its manufacturing facility is in compliance with currently applicable safety, health and environmental laws and regulations.

Employees

As of December 31, 2002, the Company had 46 full-time employees including 12 administrative, sales and supervisory personnel, 10 quality control personnel and 24 production personnel. A union does not represent the employees of the Company.

Medical Consultants

From time to time, the Company consults with medical advisors who report on advances in technology and on developments in their respective fields. During 2002 and 2001, the Company used consultants on a specific project basis. Amounts paid to consultants during 2002 and 2001 were not material.

Item 2. PROPERTIES

The manufacturing facility and offices of the Company are located in two buildings in an industrial area in Fitchburg, Massachusetts. The first building, which was purchased in April 1994, consists of a 22,000 square foot, six story building. The second building, which was purchased in September 1996, is a 94,000 square foot, two story building. We believe our current facilities are sufficient to meet our production needs through fiscal year ending December 31, 2003. A 40,000 square foot portion of the second building is not utilized at this time.

Item 3. LEGAL PROCEEDINGS

We are not a party to any material threatened or pending legal proceedings.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The results of the Company's 2002 Annual Meeting of Shareholders were reported in the Company's Form 10-Q for the quarter ending September 30, 2002.

PART II

Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

ART's Common Stock was listed on the American Stock Exchange on March 3, 1992 and trades under the ticker symbol HRT. Prior to that, ART's stock was listed on NASDAQ.

The following table sets forth, for the period indicated, the high and low sale prices per share for ART's Common Stock as quoted by the American Stock Exchange.

	High	Low
	-----	-----
Year Ended December 31, 2002		

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

1st Quarter	\$ 3.25	\$ 2.46
2nd Quarter	3.25	2.76
3rd Quarter	3.05	2.35
4th Quarter	2.96	2.51
Year Ended December 31, 2001		

1st Quarter	\$ 2.25	\$ 1.62
2nd Quarter	3.29	1.95
3rd Quarter	3.10	2.40
4th Quarter	3.10	2.26

As of February 21, 2003 the number of record holders of ART's common stock was estimated to be 1,100.

7

Dividend Policy

The Company's cash reserves would be more than adequate to facilitate a payment, but at this time, the Company does not plan to pay any dividends. The Company's revolving credit agreement contains various restrictions and conditions including restrictions regarding the payment of dividends. Future determination as to the payment of cash dividend, if any, will be at the discretion of the Board of Directors and will be dependant upon the Company's financial condition, results of operations, capital requirements, and other such factors as the Board of Directors may deem relevant, including restrictions under the credit facility.

Securities authorized for issuance under equity compensations plans

2001 Stock Option Plan

In October 2001, the shareholders of the Company approved the adoption of the 2001 Stock Option Plan (the "Option Plan") and reserved 200,000 shares of the Company's common stock for issuance under the Option Plan. Options for 30,000 shares were granted to an officer in 2001 of which 6,000 of the options were exercisable at December 31, 2002 and options with respect to 170,000 are available for future grants.

1987 Incentive Stock Option Plan

In 1987, the shareholders of the Company approved the incentive stock Option Plan (the "ISO Plan"). The ISO Plan provided for issuance of stock options for up to 250,000 shares. Under the ISO Plan, the exercise price of the options is the fair market value of the common stock on the date of grant. The range of exercise prices of options granted under the ISO Plan was \$1.06 to \$6.00 per share for all options outstanding and granted under the 1987 ISO Plan, with a weighted average exercise price of \$1.44 per share. The ISO Plan that was terminated for additional grants in 2001 currently has 26,000 outstanding and exercisable options.

Number of securities to be issued upon exercise of outstanding options, warrants	Weighted-average exercise price of outstanding options,	Number of securities remaining available for future issuance under equity compensat
--	---	---

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Plan Category	and rights	warrants and rights	plans (excluding securities reflected in column (a))
Equity compensation plan approved by security holders	56,000	\$1.74	170,000
Equity compensation plans not approved by security holders	0	\$.00	0
Totals	56,000	\$1.74	170,000

8

Item 6. SELECTED FINANCIAL DATA

(In thousands, except per share data)

The selected financial data presented below for each of the years ended December 31 has been derived from the Company's audited consolidated financial statements. The data should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and the Financial Statements, including the notes thereto, appearing elsewhere in this report.

Statements of Operations Data:	Years Ending December 31		
	2002	2001	2000
Net sales	\$ 7,192	\$ 7,220	\$ 8,522
Commissions and related revenues	-	-	1,000
Total revenue	7,192	7,220	9,522
Cost of sales	4,934	5,030	6,249
Gross profit	2,258	2,190	3,273
Selling and marketing	38	59	193
General and administrative	1,305	1,480	1,908
Research and development	52	215	229
Amortization of goodwill	-	131	130
Write-down of assets	-	-	-
Income from operations	863	305	813
Interest and other expenses, net	(1)	(72)	(148)
Income before income taxes and cumulative change in accounting principle	862	233	665
Income tax expense	52	10	45

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Income before cumulative change in accounting principal	810	223	620
Cumulative effect of change in accounting principal (net of tax)	(57)	-	-
Net income (loss)	\$ 753	\$ 223	\$ 620
	=====	=====	=====
Before cumulative effect of change in accounting principle:			
Net income (loss) per share - basic	\$.28	\$.07	\$.19
	=====	=====	=====
- diluted	\$.28	\$.07	\$.18
	=====	=====	=====
After cumulative effect of change in accounting principle:			
Net income (loss) per share - basic	\$.26	\$.07	\$.19
	=====	=====	=====
- diluted	\$.26	\$.07	\$.18
	=====	=====	=====
Weighted average number of shares outstanding			
- basic	2,875	3,010	3,333
- diluted	2,935	3,156	3,430
	2002	2001	2000
	----	----	----
Total assets	\$ 8,478	\$ 8,684	\$ 9,919
Long-term obligations (including current portion)	\$ -	\$ 113	\$ 602
Working capital	\$ 3,577	\$ 2,869	\$ 3,671
Shareholders' equity	\$ 8,098	\$ 7,913	\$ 8,560

9

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Any forward looking statements made herein are based on current expectations of the Company that involves a number of risks and uncertainties and should not be considered as guarantees of future performance. These statements are made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "expect," "anticipate," "believe," "intend," "plans," "predict," or "will." The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks and an inability to arrange additional debt or equity financing.

Results of Operations

The following table sets forth for the periods indicated, the percentages of the net sales represented by certain items reflected in the

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Company's statements of operations.

	Years ended December 31,		
	2002	2001	2000
Net sales	100.0%	100.0%	100.0%
Cost of sales	68.6	69.7	73.3
Gross profit	31.4	30.3	26.7
Selling and marketing	0.5	0.8	2.3
General and administrative	18.1	20.5	22.4
Research and development	0.7	3.0	2.7
Amortization of goodwill	-	1.8	1.5
Other (expense), net	-	(1.0)	(1.7)
GE/Prucka lump sum commission termination payment	-	-	11.7
Income before income taxes and cumulative effect of change in accounting principle	12.0	3.2	7.8
Income tax provision	0.7	(0.1)	(0.5)
Income before cumulative effect of change in accounting principal ..	11.3	3.1	7.3
Cumulative effect of change in accounting principle, net of tax	0.8	-	-
Net income	10.5%	3.1%	7.3%

Revenue

Total revenue declined from \$7,219,688 in 2001 to \$7,192,065 in 2002 and from \$9,521,863 in 2000 to \$7,219,688 in 2001. The \$27,623 decline in total revenue in 2002 was due to two factors. There was an increase of electrode component sales by \$110,374 due in part to the introduction of a radio translucent product, offset by a \$137,997 decline in the sale of computerized medical instruments. The increase in electrode component sales was the result of an increase in sales of electronic sensors of \$211,674 or 3.3% in 2002 compared to 2001 offset by a decrease in snap sales by \$77,761 in 2002 compared to 2001.

The decline in total revenue by \$2,302,175 in 2001 as compared to 2000 resulted from several factors. Revenue in 2000 included a one-time \$1,000,000 lump sum payment to buy out a sales commission agreement between ART and Prucka Engineering, Inc. (now GE Marquette Medical Systems, Inc.). Net sales of snaps distributed by Micron were lower by \$840,364 in 2001 compared to 2000. A major customer purchasing snaps directly from the original manufacturer beginning in 2000 caused this loss of snap sales. Micron's silver-plated and conductive resin sensors for disposable ECG electrodes were \$439,175 or 6.4% lower in 2001 than in 2000.

Cost of Sales

Cost of sales as a percent of revenues was 68.6% in 2002 compared to 69.7% in 2001 and 73.3% in 2000 excluding the GE/Prucka termination payment. The reduction in cost of sales in 2002 is primarily attributed to the process improvements that resulted in manufacturing efficiencies. Cost of sales in 2002 also includes an impairment

charge of \$50,923 related to obsolete electrode assembly machine parts. The reduction from 2000 to 2001 was primarily due to the higher sales mix of snaps in 2000.

Selling and Marketing

Selling and marketing expenses decreased \$20,999, or 36% in 2002 compared to 2001 and \$133,877, or 69% from 2000 to 2001. This was due primarily to the decision to eliminate direct sales and sales support personnel engaged in promoting ART SAECG Products. While the conversion of the Predictor series to a Windows version is complete, the Company plans to market this software under license through original equipment manufacturers and expects to avoid future expenses by ART on sales and marketing services.

General and Administrative Expenses

General and administrative expenses were \$175,587 lower in 2002 than in 2001. The savings in 2002 resulted from the reduction of administrative payroll from final severance associated with the closing of the Texas office, and reductions at the Fitchburg office. Even with this reduction the Company incurred approximately \$111,000 of legal expenses and \$25,600 in other professional and corporate expenses in the year ended December 31, 2002 related to an attempt to acquire certain business assets of a competitor of Micron Products Inc. The negotiations to acquire the assets were discontinued in July 2002. Better containment of legal and other administrative expenses contributed to the reductions as compared to prior years.

General and administrative expenses were \$427,967 lower in 2001 than in 2000. The savings in 2001 resulted primarily from the severance of three officers of the Company in 2000 and the assignment of their duties to other management personnel or outside consultants in 2001. Savings in 2001 related to reduced costs associated with the office of the Presidency were approximately \$102,000, reduced costs associated with investor relations and investor related legal costs were approximately \$53,000. Additionally, legal expenses were \$74,000 less in 2001 as a result of the completion of an environmental investigation concerning Micron facilities with no adverse actions.

Research and Development

Research and development costs decreased from \$229,659 in 2000, \$214,872 in 2001, to \$52,456 in 2002 due to the termination of ART's full time technician and the significant decrease in the use of outside consultants with respect to software development. Included in the \$71,000 of cost for 2001 and \$24,220 of cost for 2002 was the outside programming service used to complete the Predictor(R)7 conversion. This cost is not expected to recur in 2003. Micron spent the remaining \$28,236 in 2002 on its development of a sensor to be marketed in the Pacific Rim. Funding for future research and development is expected to come from cash provided by ongoing operations.

Interest Expense

Interest expense was \$15,932 in 2002, \$64,412 in 2001 and \$91,477 in 2000. Interest expense of \$5,729 in 2002, \$48,055 in 2001, and \$63,250 in 2000 is related to the 11% bonds, a majority of which were redeemed in 2001. The remaining bonds with a face value of \$125,000 matured in May 2002. Interest expense also includes a \$10,000 annual charge for unutilized borrowing base on our \$1,000,000 revolving loan.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Other Income (Expense)

Included in other income (expense) is amortization expense of \$11,972 in 2002, \$138,538 in 2001, and \$63,490 in 2000 for the discount recorded on the 11% Bonds. The decrease of amortization expense of \$126,566 in 2002 was caused by the early redemption of \$425,000 of bonds 2001. This expense was offset by interest income on the cash and cash equivalents balance.

Income Taxes

Income taxes as a percent of income before income taxes was 6% in 2002, 4.3% in 2001, and 6.8% in 2000. In these years the Company had no current Federal income tax expense due to Net Operating Loss Carryforwards and available deferred tax assets. The tax expense for 2002, 2001, and 2000 is for state taxes, principally in Massachusetts where Micron is located.

11

Earnings Per Share

The Company has an ongoing stock repurchase program, which resulted in the repurchase of 270,413 shares of the Company's common stock in 2002. The reduction in the number outstanding shares has had the effect of increasing the Company's earnings per share as reported. This decrease in the weighted average number of shares outstanding has had the effect of increasing the basic earnings per share as reported in 2002 by \$.01.

Liquidity and Capital Resources

Working capital was \$3,577,424 as of December 31, 2002, \$2,869,344 at December 31, 2001 and \$3,671,443 at December 31, 2000. The \$708,080 increase in working capital in 2002 was mostly attributable to the operating cash flows of \$824,327 and the maturing of the remaining bond debt in May of 2002. The \$802,099 decrease in working capital in 2001 was mainly attributed to \$622,030 of payments to the early retirement of the principal and repurchase the associated warrants of the 11% bonds in 2001, and the \$1,000,000 GE/Prucka commission agreement termination payment inflating the position in 2000. Cash and cash equivalents were \$1,773,412, \$1,860,822, and \$1,999,292 at December 31, 2002, 2001, and 2000 respectively. Substantially all these funds are invested in fixed rate bank instruments that are highly liquid.

In addition, the announced program of acquiring the Company's common stock resulted in a non-operating use of funds aggregating \$730,837 (270,413 shares) in 2002, \$702,615 (305,859 shares) in 2001, and \$502,772 (265,040) shares in 2000. The Company expanded its Stock Buy Back Program on December 24, 2002 authorizing an additional \$600,000 worth of stock to be purchased from time to time as determined by management based upon market conditions.

Inventories increased by \$226,978 in 2002 as compared to \$36,926 in 2001. The increased use of capital to fund inventory is the result of carrying a larger quantity of radio translucent base resin, and manufactured product. The resin inventory was necessary to adequately insure materials would be readily available for production demands at a reasonable cost. The increased final product inventory is resulting from lower than expected shipments of radio translucent in 2002, and the remaining inventory increase from the terminated attempt to purchase a competitor.

Essentially all of the capital equipment expenditures of \$420,013

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

(\$219,325 net of disposals) in 2002, \$675,111 in 2001 and \$246,658 in 2000 were related to the electrode sensor operation at Micron. In 2002, a \$200,000 decrease in capital equipment relates to the sale of \$130,000 of attaching machines, \$51,000 long lived asset impairment and other miscellaneous disposals of equipment. As in prior years, the expected capital expenditures of \$400,000 for machinery and equipment in 2003 in the electrode sensor operation will be derived from net operating cash flows.

The Company has a \$1 million line of credit with a bank that has been renewed through May 2003. There were no borrowings under the line of credit in 2002, 2001 or 2000. The Company anticipates evaluating the line of credit before its renewal again in 2003.

Inflation

The Company does not believe that inflation in the United States or international markets in recent years has had a significant effect on its results of operations.

Factors that may affect future operating results

In addition to the other information in this Form 10-K, the following factors should be considered in evaluating the Company and its business. The risks and uncertainties described below are not the only ones facing the Company. Additional risks and uncertainties that the Company does not presently know or currently deems immaterial may also impair the Company's business, results of operations and financial conditions.

The Company could become involved in litigation over intellectual property rights

The medical device industry has been characterized by extensive litigation regarding patents and other intellectual property rights. Litigation, which would likely result in substantial cost to us, may be necessary to enforce any patents issued or licensed to us and/or to determine the scope and validity of others' proprietary rights.

12

In particular, our competitors and other third parties hold issued patents and are assumed to hold pending patent applications, which may result in claims of infringement against us or other patent litigation. The Company also may have to participate in interference proceedings declared by the United States Patent and Trademark Office, which could result in substantial cost, to determine the priority of inventions

If trade secrets are not kept confidential, the secrets may be used by others to compete against us

Micron relies on unpatented trade secrets to protect its proprietary process. There are no assurances that others will not independently develop or acquire substantially equivalent technologies or otherwise gain access to our proprietary process. Ultimately the meaningful protection of such unpatented proprietary technology cannot be guaranteed. The Company relies on confidentiality agreements with its employees. Remedies for any breach by a party of these confidentiality agreements may not be adequate to prevent such actions. Failure to maintain trade secret protection, for any reason, could have a material adverse effect on us.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Dependence on a limited number of customers

In the fiscal years 2002 and 2001, 75% and 78%, respectively of the Company's revenues was derived from three customers. The loss of any one or more of these customers would have an immediate significant adverse effect on our financial results. In an effort to maintain this customer base, more favorable terms than might otherwise be agreed to could be granted. Currently, the Company generally does not receive purchase volume commitments extending beyond several months. Large corporations can shift focus away from a need for our product with little or no warning.

The vast majority of revenues are derived from the sale of a single product

In fiscal years 2002 and 2001, the Company derived 92% and 88%, respectively, of its income from medical electrode sensors for use in disposable electrodes. While the technology in electrode sensors has been used for many years, there is no assurance that a new patented or unpatented technology might not replace the existing market for disposable electrode sensors. Any substantial technological advance that eliminates our product will have a material adverse effect on our operating results.

A product liability suit could adversely effect on operating results.

The testing, manufacture, marketing and sale of medical devices of our customers entail the inherent risk of liability claims or product recalls. If our customers are involved in a lawsuit it is foreseeable that the company would also be named. Although, the Company maintains product liability insurance, coverage may not be adequate. Product liability insurance is expensive, and in the future may not be available on acceptable terms, if at all. A successful product liability claim or product recall could have a material adverse effect on our business, financial condition, and ability to market product in the future.

The Company is subject to stringent environmental regulations.

The Company is subject to a variety of Federal, state and local requirements governing the protection of the environment. These environmental regulations include those related to the use, storage, handling, discharge and disposal of toxic or otherwise hazardous materials used in or resulting from the Company's manufacturing processes. Failure to comply with environmental law could subject the Company to substantial liability or force use to significantly change our manufacturing operations. In addition, under some of these laws and regulations, the Company could be held financially responsible for remedial measures if its properties are contaminated, even if it did not cause the contamination.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with generally accepted accounting principles requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to Consolidated Financial Statements describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

A critical accounting policy is defined as one that is both material to the presentation of the Company's financial statements and requires management to make difficult, subjective or complex judgments that could have a material

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

effect on the Company's financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company's financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company's operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section below entitled "Factors that could affect future results." Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company's consolidated financial statements are fairly stated in accordance with generally accepted accounting principles, and present a meaningful presentation of the Company's financial condition and results of operations.

Management believes that the following are critical accounting policies:

Revenue Recognition and Accounts Receivable

Revenues from the sale of products are recorded when the product is shipped, title and risk of loss have transferred to the purchaser, payment terms are fixed or determinable and payment is reasonably assured.

Based on management's on-going analysis of accounts receivable balances, and after the initial recognition of the revenue, if an event occurs which adversely affects the ultimate collectibility of the related receivable, management will record an allowance for bad debts. Bad debts have not had a significant impact on our financial position, results of operations and cash flows.

Inventory and Inventory Reserves

The Company values its inventory at the lower of cost or market. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. If actual market conditions are less favorable than those projected by management, additional inventory may be required.

The Company maintains a reserve for excess, slow moving, and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value. A review of inventory on hand is made at least annually and provisions for excess and obsolete inventory is recorded. The review is based on several factors including a current assessment of future product demand, historical experience, and product expiration.

Deferred Tax Assets

The Company records a valuation allowance to reduce its deferred tax

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

assets to the amount that is more likely than not to be realized. While the Company has considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment to the deferred tax asset would increase income in the period such a determination was made.

Asset Impairment - Goodwill

The Company reviews the valuation of goodwill and intangible assets to assess potential impairments. The management reassesses the useful lives of goodwill and other intangible assets in accordance with the guidelines set forth in FASB Statement No. 142, "Goodwill and Other Intangible Assets". The value assigned to intangible assets is determined by a valuation based on estimates and judgment regarding expectations for the success and life cycle of products

14

acquired from Newmark or others in the future. If the actual sale of product and market acceptance differs significantly from the estimates, management may be required to record an impairment charge to write down the asset to its realizable value. To test for impairment, a present value of an estimate of future cash flows related to the intangible asset are calculated compared to the value of the intangible asset. When impairment exists it could have a material adverse effect on the Company's business, financial condition and results of operations.

Asset Impairment - Long Lived Assets

The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. When we determine that the carrying value of such assets may not be recoverable, we generally measure any impairment on a projected discounted cash flow method using a discount rate determined by our management to be commensurate with the risk inherent in our current business model. Included in cost of sales for 2002 is an impairment charge of \$50,923 related to machine parts, which were used in the electrode assembly machine leasing business. The parts were determined to have no future utilization and therefore were fully impaired.

Recently Issued Accounting Standards

Stock-Based Compensation

In December 2002, The Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 148 ("SFAS 148"), "Accounting for Stock-Based Compensation - Transition and Disclosure" which amends Statement of Financial Accounting Standard No. 123, "Accounting for Stock-Based Compensation," to provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. It also amends the disclosure provisions of that Statement to require prominent disclosure about the effect on reported net income of an entity's accounting policy decisions with respect to stock-based employee compensation. Finally, this Statement amends Accounting Principles Board Opinion No. 28, "Interim Financial Reporting," to require disclosure about those effects in interim financial information.

Exit or Disposal Activities

In June 2002, The Financial Accounting Standards Board issued Statement

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

of Financial Accounting Standard No. 146 ("SFAS 146"), "Accounting for Costs Associated with Exit or Disposal Activities" which addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force ("EITF") Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (including Certain Costs Incurred in a Restructuring)." SFAS 146 is effective for exit or disposal activities initiated after December 31, 2002. The adoption of SFAS 146 is not expected to have a material effect on the Company's consolidated financial statements.

New Accounting Standards Implemented

Long-Lived Assets

In 2002, the Company adopted Statement of Financial Accounting Standards No 144 ("SFAS 144") "Accounting for the Impairment or Disposal of Long-Lived Assets", which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. Although SFAS 144 supersedes Statement of Financial Accounting Standard No. 121 ("SFAS 121"), "Accounting for the Impairment of Long-Lived Assets To Be Disposed Of", it retains many of the fundamental provisions of SFAS 121. SFAS 144 also supersedes the accounting and reporting provisions of Accounting Principles Board Opinion No. 30 ("APB 30"), "Reporting the Results of Operations—Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions" for the disposal of a segment of a business. However, it retains the requirement of APB 30 to report separately discontinued operations and extends that reporting to a component of an entity that either has been disposed of, by sale, abandonment, or in a distribution to owners, or is classified as held for sale. The adoption of SFAS 144 did not have a material effect on the Company's consolidated financial statements.

Included in cost of sales for 2002 is an impairment charge of \$50,923 related to machine parts which were used in the electrode assembly machine leasing business. The parts were determined to have no future utilization.

15

Goodwill

Effective January 1, 2002 the Company adopted FASB Statement No.141, "Business Combinations" ("SFAS 141") and No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). SFAS 141 requires the use of the purchase method of accounting and prohibits the use of the pooling-of-interest method of accounting for business combinations initiated after June 30, 2001. SFAS 141 also requires that the Company recognize acquired intangible assets apart from goodwill if the acquired intangible assets meet certain criteria. SFAS 141 applies to all business combinations initiated after June 30, 2001 and for purchase business combinations completed on or after July 1, 2001. It also requires, upon adoption of SFAS 142 that the Company reclassify the carrying amounts of intangible assets and goodwill based on the criteria in SFAS 141.

SFAS 142 requires, among other things, that companies no longer amortize goodwill, but test goodwill for impairment at least annually. In addition, SFAS 142 requires that the Company identify reporting units for the purpose of assessing potential future impairments of goodwill, reassess the useful lives of other existing recognized intangible assets, and cease amortization of intangible assets with an indefinite useful life. An intangible asset with an indefinite useful life should be tested for impairment in accordance with the guidelines in SFAS 142. SFAS 142 is required to be applied

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

to all goodwill and other intangible assets regardless of when those assets were initially recognized.

As of January 1, 2002, the Company's goodwill of \$1,326,000 was composed of \$82,000 associated with attaching machine assets purchased from Newmark, Inc. in 1997 and \$1,244,000 associated with the acquisition of Micron Products Inc. in 1992. As a result of the transitional impairment tests, the goodwill associated with the Newmark agreement was determined to be impaired as determined by using the present value of future cash flows solely related to attaching machines. The balance of \$82,000 (\$57,000 net of tax) is being reported as the cumulative effect of change in accounting principle for the twelve months ended December 31, 2002. The diminishing number of leases and sales of attaching machines used for the assembly of disposable medical electrodes in this mature industry lead to the impairment of Newmark goodwill. No adjustment to the \$1,244,000 balance of goodwill associated with the Micron Products acquisition was deemed necessary as of December 31, 2002.

The continued effect on reported net income due to the cumulative effect of change in accounting principle, and the discontinuance of goodwill amortization is as follows:

	2002	2001	2000
Reported net income	\$ 752,736	\$ 222,629	\$ 620,127
Cumulative effect of change in accounting principle	57,000	-	-
Goodwill amortization	-	130,833	129,889

Adjusted net income before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$ 809,736	\$ 335,867	750,016
=====			
Basic net income per share as reported	\$.26	\$.07	\$.19
Cumulative effect of change in accounting principle	.02	-	-
Goodwill amortization		.05	.04

Basic net income per share before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$.28	\$.12	\$.23
=====			
Diluted net income per share as reported	\$.26	\$.07	\$.18
Cumulative effect of change in accounting principle	.02	-	-
Goodwill amortization	-	.04	.04

Diluted net income per share before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$.28	\$.11	\$.22
=====			

Item 7A. Quantification and Qualitative Disclosures About Market Risk

The Company is not directly exposed to foreign currency exchange risk as all business is conducted based in U.S. Dollars. However, our foreign

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

customers revenue, expense and capital spending are transacted in their local currencies. As a result weak, economic conditions in foreign markets could affect our results. We do not use derivative instruments to hedge foreign risk and we believe our allowances are adequate for these risks.

Item 8. Financial Statements and Supplementary Data

The information required by this item may be found on pages F-1 through F-27 of this Annual Report on Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

There have been no changes in or disagreements with accountants on accounting or financial disclosure matters.

PART III

Item 10. Directors and Executive Officers of the Registrant.

The information with respect to directors and executive officers required under this item is incorporated by reference to the information set forth under the section entitled "Election of Directors" and "Executive Officers" in our proxy statement for our 2003 Annual Meeting of Shareholders to be held on May 2, 2003. Information relating to compliance with beneficial ownership reporting requirements is contained in our proxy statement for our 2003 Annual Meeting of Shareholders under the section entitled "Section 16(a) Beneficial Ownership Reporting Compliance." and is incorporated herein by reference.

Item 11. Executive Compensation.

The information required under this item is incorporated by reference to the section entitled "Compensation of Executive Officers" in our proxy statement for our 2003 Annual Meeting of Shareholders and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management.

The information required under this item is incorporated by reference to the section entitled "Stock Ownership Information" in our proxy statement for our 2003 Annual Meeting of Shareholders and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions.

The information required under this item is incorporated by reference to the section entitled "Certain Relationships and Related Transactions" in our proxy statement for our 2003 Annual Meeting of Shareholders and is incorporated herein by reference.

Item 14. Controls and Procedures

Within ninety days prior to the filing date of this report, the Disclosure Committee including James E. Rouse as President and Chief Executive Officer and David A Garrison as Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures. Under rules promulgated by the SEC, disclosure controls and procedures are defined as those controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Based on the evaluation of the Company's disclosure controls

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

and procedures, it was determined that such controls and procedures were effective as of the date of the conclusion of the evaluation.

Further, there were no significant changes in the Company's internal controls or in other factors that could significantly affect these controls after the date of the conclusion of their most recent evaluation. It should be noted that the design of any system of controls is based on assumptions about future events, and there can be no assurance that any design will succeed under all future conditions.

17

PART IV

Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.

(a) List of documents filed as a part of this report:

1. All Financial Statements - See index to financial statements on page F-1.
2. Financial Statement Schedules as attached on page F-26 and F-27.
 - i. Schedule II -All schedules for which provision is made in Regulation S-X of the Securities and Exchange Commission not included here are omitted as the required information is inapplicable or the information is presented in the financial statements or related notes.
3. List of Exhibits

The exhibits listed on page 17 and 18 are filed as part of and incorporated by reference into, this Annual Report on Form 10-K

(b) Reports filed in the fourth quarter on Form 8-K

1. On December 23, 2002 a form 8-K was filed detailing under item 5 a stock buyback program.
2. On November 1, 2002 a form 8-K was filed detailing under item 5 the appointment of a Chief Executive Officer and Chief Financial Officer and the results of the shareholder votes during the 2001 annual meeting.

(c) Exhibits

The Company hereby files as part of this Annual Report on Form 10-K the exhibits listed in 15(a)(3) set forth above. Exhibits, which are incorporated herein by reference, may be inspected and copied at the public reference facilities maintained by the SEC at Room 1024, Washington, D.C. 20549. Copies of such material may be obtained by mail from the Public Reference Section of the SEC at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at the address "<http://www.sec.gov>".

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

By: /s/ James E Rouse

James E. Rouse,
President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Capacity	Date
-----	-----	-----
/s/ James E. Rouse	President and Chief Executive Officer	March 18, 20

James E. Rouse	(Principal Executive Officer)	
/s/ David A. Garrison	Chief Financial Officer	March 18, 20

David A. Garrison	(Principle Financial and Accounting Officer)	
/s/ E. P. Marinos	Chairman of the Board	March 18, 20

E. P. Marinos		
/s/ Russell C. Chambers	Director	March 18, 20

Russell C. Chambers		
/s/ Julius Tabin	Director	March 18, 20

Julius Tabin		
/s/ Paul F. Walter	Director	March 18, 20

Paul F. Walter		
/s/ James E. Rouse	Director	March 18, 20

James E. Rouse		

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

CERTIFICATION

I, James E. Rouse, certify that:

1. I have reviewed this annual report on Form 10-K of Arrhythmia Research Technology, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
 - a. designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 - b. evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and
 - c. presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions in regard to significant deficiencies and material weaknesses.

DATE: March 18, 2003

/s/ James E. Rouse

James E. Rouse
President and Chief Executive Officer

20

CERTIFICATION

I, David A. Garrison, certify that:

1. I have reviewed this annual report on Form 10-K of Arrhythmia Research Technology, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
 - a. designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 - b. evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and
 - c. presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions in regard to significant deficiencies and material weaknesses.

DATE: March 18, 2003

/s/ David A. Garrison

David A. Garrison
Chief Financial Officer

21

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
3.0	Articles of Incorporation
3.1	By-laws
3.2	Certificate of Agreement of Merger of Arrhythmia Research Technology, Inc., a Louisiana Corporation, and Arrhythmia Research Technology, Inc., a Delaware Corporation. ...
3.3	Articles of Merger of Arrhythmia Research Technology, Inc., a Louisiana Corporation and Arrhythmia Research Technology, Inc., a Delaware corporation.
4.0	Form of Certificate evidencing shares of the Company's Common Stock.
4.2	Form of Option to purchase Company Common Stock under the 1987 Incentive Stock Option Plan
4.4	Bond Indenture and Bond Form
4.5	Form of Option for E.P. (Lou) Marinos under 1995 Key Employees Stock Option Plan
10.2	Lockup Agreement.
10.3	Manufacturing Agreement by and between ART and Mortara Instrument, Inc. dated March 15, 1987.
10.4	Amendment to Manufacturing agreement dated June 15, 1987.
10.5	Letter agreement by and between ART and Mortara Instrument, Inc. dated October 26, 1987.
10.6	Letter agreement by and between ART and Mortara Instrument, Inc. dated February 21, 1988.
10.7	Letter agreement by and between ART and Mortara Instrument, Inc. dated February 21, 1988.
10.8	Letter agreement by and between ART and Mortara Instrument, Inc. dated July 31, 1988.
10.9	License Agreement dated November 15, 1981 by and between University Patents, Inc., and ART.
10.10	Amendment to License Agreement dated June 1, 1985.
10.11	License of Cardiac Signal Average and Base Technology by ART to Cardiodigital Industries, Inc.
10.12	Grant of Option to Acquire Exclusive License for Use of Signal Averaging Technology by Cardiodigital Industries, Inc. to ART.
10.13	Agreement and Plan of Merger executed by ART and Arrhythmia Research Technology, Inc., a Louisiana corporation.
10.16	Amendment No. 2 to License Agreement between ART and University Patents, Inc. dated June 6, 1991.
10.22	Asset Purchase Agreement, dated February 17, 1993, by and among Hubbard, Thurman, Tucker & Harris, L.L.P. and ART related to Corazonix.
10.23	Agreement and Plan of Merger, dated November 25, 1992, among Arrhythmia Research Technology, Inc., ART Merger Subsidiary II, Inc., Micron Products, Inc. and Micron Medical Products, Inc.
10.24	Merger Agreement, dated November 25, 1992, between ART Merger Subsidiary II, Inc. and Micron Products, Inc.
10.25	Asset Purchase Agreement, dated July 9, 1993, between Arrhythmia Research Technology, Inc. and Corazonix Corporation.
10.26	Amendment to Asset Purchase Agreement, dated November 5, 1993, between Arrhythmia Research Technology, Inc. and Corazonix Corporation.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

10.34	Asset Purchase Agreement, dated March 5, 1997, between Micron Products, Inc. and N
10.40	Employment agreement between James E. Rouse and the Company dated October 5th, 200
28.0	1987 Incentive Stock Option Plan
28.09	Merger Agreement, dated December 26, 1993, between Micron Products, Inc. and Micro Products, Inc
28.10	Articles of Merger of Parent and Subsidiary
28.11	Consent Judgment signed by Arrhythmia Research Technology, Inc. and Corazonix Corp entered on November 15, 1993.
21.0	Subsidiaries
99.6	2001 Stock Option Plan
99.7	Certification pursuant to 18 U.S.C.ss.1350, as adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002 X-2
(a)	Incorporated by reference from the Company's Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW.
(b)	Incorporated by reference from the Company's Form 10-K for fiscal year ended December 31, 1989 as filed with the Commission in March 1990.
(c)	Incorporated by reference from the Company's Registration Statement on Form S-1 as filed with the Commission in August 1990, Registration Statement No. 33-36607.
(d)	Incorporated by reference from the Company's Form 10-K for fiscal year ended December 31, 1996 as filed with the Commission in March 1997.
(e)	Incorporated by reference from the Company's Form 8-K as filed with the Commission on December 10, 1992.
(f)	Incorporated by reference from the Company's Form 10-K for fiscal year ended December 31, 1992 as filed with the Commission in March 1993.
(g)	Incorporated by reference from the Company's Form 8-K as filed with the Commission on July 15, 1993. (h) Incorporated by reference from the Company's Form 8-K as filed with the Commission on November 22, 1993. (i) Incorporated by reference from the Company's Form 8-K as filed with the Commission on June 30, 1998. (j) Incorporated by reference from the Company's Form 10-K for fiscal year ended December 31, 2001 as filed with the Commission in March 2002.
(k)	Incorporated by reference from the Company's Form 10-Q for period ended September 30, 2002 as filed with the Commission in November 2002.
(l)	Incorporated by reference from the Company's Form 10-K for fiscal year ended December 31, 1997 as filed with the Commission in March 1998.
(m)	Incorporated by reference from the Company's Form 10-Q as exhibit 10.10 for period ended September 30, 2002 as filed with the Commission in November 2002.

Arrhythmia Research Technology, Inc.

And Subsidiary

Contents

Independent Auditors' Report	F-2
Consolidated Financial Statements:	
Balance sheets	F-3, F-4
Statements of income	F-5
Statements of changes in shareholders' equity	F-6
Statements of cash flows	F-7
Notes to consolidated financial statements	F-8 to F-25

F-1

Independent Auditors' Report

To the Shareholders of
Arrhythmia Research Technology, Inc.

We have audited the accompanying consolidated balance sheets of Arrhythmia Research Technology, Inc. and Subsidiary as of December 31, 2002 and 2001, and the related consolidated statements of income, changes in shareholders' equity and cash flows for each of the three years in the period ended December 31, 2002. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Arrhythmia

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Research Technology, Inc. and Subsidiary as of December 31, 2002 and 2001, and the consolidated results of their operations and their cash flows for each of the three years in the period ended December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 2 to the consolidated financial statements, the Company in 2002 adopted the provisions of Statement of Financial Accounting Standards SFAS No. 142, "Goodwill and Other Intangible Assets".

/s/ BDO Seidman, LLP
Gardner, Massachusetts
February 14, 2003

F-2

Arrhythmia Research Technology, Inc.
and Subsidiary

Consolidated Balance Sheets

December 31,	2002
=====	
Assets	
Current assets:	
Cash and cash equivalents	\$1,773,412
Trade accounts receivable, net of allowance for doubtful accounts of \$39,000 and \$51,000	979,774
Inventories (Note 3)	1,124,065
Deposits, prepaid expenses and other current assets	79,726

Total current assets	3,956,977
Property, plant and equipment, net (Note 4)	2,831,836
Goodwill (Note 2)	1,244,000
Deferred income taxes, net (Note 6)	444,923

Total assets	\$8,477,736
=====	

See accompanying notes to consolidated financial statements.

F-3

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Arrhythmia Research Technology, Inc.
and Subsidiary

Consolidated Balance Sheets

December 31, 2002

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable	\$ 156,275
Accrued expenses	223,278
Current maturities of bonds payable (Note 5)	-

Total current liabilities	379,553
---------------------------	---------

Commitments and contingencies (Notes 7 and 8):

Shareholders' equity (Notes 2 and 11):

Preferred stock, \$1 par value; 2,000,000 shares authorized; none issued	-
Common stock, \$.01 par value; 10,000,000 shares authorized; 3,888,131 and 3,758,181 issued, respectively	38,881
Additional paid-in-capital	9,161,707
Common stock held in treasury, 1,139,718 and 869,305 shares at cost	(3,088,116)
Retained earnings	1,985,711

Total shareholders' equity	8,098,183
----------------------------	-----------

Total liabilities and shareholders' equity	\$8,477,736
--	-------------

See accompanying notes to consolidated financial statements.

F-4

Arrhythmia Research Technology, Inc.

and Subsidiary

Consolidated Statements of Income

Years ended December 31, 2002 2001

Net sales	\$ 7,192,065	\$ 7,219,688
Commission and related revenue (Note 8)	-	-

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Total revenue (Note 12)	7,192,065	7,219,688
Cost of sales	4,934,307	5,029,922

Gross profit	2,257,758	2,189,766
Selling and marketing	37,986	58,985
General and administrative	1,304,663	1,480,250
Research and development	52,456	214,872
Amortization of goodwill (Note 2)	-	130,833

Income from operations	862,653	304,826
Other income (expense):		
Interest expense	(15,932)	(64,412)
Other income (expense), net	15,015	(7,785)

Total other expense, net	(917)	(72,197)

Income before income taxes and cumulative effect of change in accounting principle	861,736	232,629

Income tax provision (Note 6):		
Current	52,000	10,000
Deferred	-	-

	52,000	10,000

Income before cumulative effect of change in accounting principle	809,736	222,629
Cumulative effect of change in accounting principle, net of income taxes of \$25,000 (Note 2)	(57,000)	-

Net income	\$ 752,736	\$ 222,629
=====		
Earnings per share (Note 2):		
Before cumulative effect of change in accounting principle:		
Basic	\$ 0.28	\$ 0.07
Diluted	\$ 0.28	\$ 0.07
After cumulative effect of change in accounting principle:		
Basic	\$ 0.26	\$ 0.07
Diluted	\$ 0.26	\$ 0.07

See accompanying notes to consolidated financial statements.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Arrhythmia Research Technology, Inc.
and Subsidiary

Consolidated Statements of Changes in Shareholders' Equity

(Notes 5 and 11)

	Shares	Amount	Paid-in Capital	Treasury Stock	
December 31, 1999	3,711,883	\$37,119	\$8,946,293	\$(1,151,892)	\$
Issuance of common stock	17,798	178	26,322	-	
Treasury stock purchase of 265,040 shares	-	-	-	(502,772)	
Value of warrants issued with bond renewal	-	-	194,000	-	
Net income	-	-	-	-	
December 31, 2000	3,729,681	37,297	9,166,615	(1,654,664)	
Issuance of common stock	28,500	285	29,996	-	
Treasury stock purchase of 305,859 shares	-	-	-	(702,615)	
Warrants repurchased	-	-	(197,030)	-	
Net income	-	-	-	-	
December 31, 2001	3,758,181	37,582	8,999,581	(2,357,279)	
Treasury stock purchase of 270,413 shares	-	-	-	(730,837)	
Exercise of stock options and warrants	129,950	1,299	162,126	-	
Net income	-	-	-	-	
December 31, 2002	3,888,131	\$38,881	\$9,161,707	\$(3,088,116)	\$

See accompanying notes to consolidated financial statements.

F-6

Arrhythmia Research Technology, Inc.
and Subsidiary

Consolidated Statements of Cash Flows

(Note 9)

Years ended December 31,	2002	2001
Cash flows from operating activities:		
Net income	\$ 752,736	\$ 222,629

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Adjustments to reconcile net income to net cash provided by operating activities:		
Cumulative effect of change in accounting principle	82,000	-
Impairment of long-lived assets	50,923	-
Director fees paid in stock	-	-
Depreciation	609,158	713,477
Provision for doubtful accounts	12,167	1,827
Amortization	11,972	317,401
Deferred income tax provision	-	-
Deferred revenue	-	(4,621)
Changes in operating assets and liabilities:		
Trade accounts receivable	(137,515)	747,888
Inventories	(226,978)	(36,926)
Deposits, prepaid expenses and other assets	(51,839)	66,359
Income taxes recoverable	-	100,000
Accounts payable and accrued expenses	(278,297)	(94,868)

Net cash provided by operating activities	824,327	2,033,166

Cash flows from investing activities:		
Capital expenditures, net of disposals	(219,325)	(675,111)
Other intangibles	-	-

Net cash used in investing activities	(219,235)	(675,111)

Cash flows from financing activities:		
Issuance of common stock	163,425	30,281
Purchase of warrants	-	(197,030)
Payments on long-term debt and capital leases	(125,000)	(627,161)
Purchase of treasury stock	(730,837)	(702,615)

Net cash used in financing activities	(692,412)	(1,496,525)

Net increase (decrease) in cash and cash equivalents	(87,410)	(138,470)
Cash and cash equivalents, beginning of year	1,860,822	1,999,292

Cash and cash equivalents, end of year	\$ 1,773,412	\$ 1,860,822
=====		

See accompanying notes to consolidated financial statements.

F-7

Arrhythmia Research Technology, Inc.

and Subsidiary

Notes to Consolidated Financial Statements

1. Description of Arrhythmia Research Technology, Inc. ("ART"), a

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Business Delaware corporation, is engaged in sales and licensing of medical software for monitoring, analyzing and treating heart disease. Micron Products, Inc. ("Micron"), a Massachusetts corporation, a wholly-owned subsidiary of ART, is a manufacturer of silver/silver chloride-plated sensor elements, a component primarily used in the manufacture of disposable medical electrodes designed for electrocardiograph ("ECG"). Additionally, Micron also acts as a distributor of metal snap fasteners, another component used in the manufacture of disposable medical electrodes. Micron manufactures and leases high speed electrode assembly machines to its sensor and snap customers.

2. Accounting Policies

Principles of Consolidation The consolidated financial statements include the accounts of ART and Micron (collectively the "Company"). All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition Revenue from product sales is recognized upon shipment of the product when independent sales representatives or distributors are responsible for installation of systems, as the title and risk of loss passes to the customer at the time of shipment. However, in cases where ART personnel are scheduled to perform this in-service/installation, the revenue is not recognized until completion of such obligations.

Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions. The Company considers highly liquid investments that can be readily converted to cash at par value to be cash equivalents.

Inventories Inventories are stated at the lower of cost or market. Cost of inventories is determined by the first-in, first-out method.

Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, as defined by SFAS No. 105, consist primarily of trade accounts receivable and cash and cash equivalents.

Accounts receivable are customer obligations due under normal trade terms. ART's customer base for ECG products is primarily comprised of hospitals and to a much lesser extent of cardiologists and office based practitioners. Micron products are sold to manufacturers of disposable electrodes, who are typically large diversified medical product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against significant credit risk.

Senior management reviews accounts receivable on a monthly basis to determine if any receivables will potentially be uncollectible. The Company includes any accounts receivable balances that are determined to be uncollectible, along with a general reserve, in our overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available to us, we believe our allowance for doubtful accounts as of December 31, 2002 is adequate. However, actual write offs might exceed the recorded allowance.

It is the Company's policy to place its cash and cash equivalents in high quality financial institutions. The Company does not believe significant credit risk exists with respect to these institutions.

F-8

Arrhythmia Research Technology, Inc.

and Subsidiary

Notes to Consolidated Financial Statements

2. Accounting Policies
(Continued)

Advertising
Expenses

Advertising expenses consist primarily of costs incurred in promoting the Company's products, printed brochures and other activities. The Company expenses advertising costs as incurred. The Company's advertising expense was approximately \$2,000, \$4,000 and \$16,000 in 2002, 2001 and 2000, respectively.

Property, Plant
and Equipment

Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.

Goodwill

Effective January 1, 2002 the Company adopted FASB Statement No.141, "Business Combinations" ("SFAS 141") and No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). SFAS 141 requires the use of the purchase method of accounting and prohibits the use of the pooling-of-interest method of accounting for business combinations initiated after June 30, 2001. SFAS 141 also requires that the Company recognize acquired intangible assets

apart from goodwill if the acquired intangible assets meet certain criteria. SFAS 141 applies to all business combinations initiated after June 30, 2001 and for purchase business combinations completed on or after July 1, 2001. It also requires, upon adoption of SFAS 142, that the Company reclassify the carrying amounts of intangible assets and goodwill based on the criteria in SFAS 141.

SFAS 142 requires, among other things, that companies no longer amortize goodwill, but test goodwill for impairment at least annually. In addition, SFAS 142, requires that the Company identify reporting units for the purpose of assessing potential future impairments of goodwill, reassess the useful lives of other existing recognized intangible assets, and cease amortization of intangible assets with an indefinite useful life. An intangible asset with an indefinite useful life should be tested for impairment in accordance with the guidelines in SFAS 142. SFAS 142 is required to be applied to all goodwill and other intangible assets regardless of when those assets were initially recognized.

As of January 1, 2002, the Company's goodwill of \$1,326,000 was composed of \$82,000 associated with attaching machine assets purchased from Newmark, Inc. in 1997 and \$1,244,000 associated with the acquisition of Micron Products Inc. in 1992. As a result of the transitional impairment tests, the goodwill associated with the Newmark agreement was determined to be impaired as determined by using the present value of future cash flows solely related to attaching machines. The balance of \$82,000 (\$57,000 net of tax) is being reported as the cumulative effect of change in accounting principle in 2002. The diminishing number of leases and sales of attaching machines used for the assembly of disposable medical electrodes in this mature industry lead to the impairment of Newmark goodwill. No adjustment to the \$1,244,000 balance of goodwill associated with the Micron Products acquisition was deemed necessary as of December 31, 2002.

F-9

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

2. Accounting Policies
(Continued)

Goodwill (Continued)	The effect on reported net income due to the cumulative effect of change in accounting principle and discontinuance of goodwill amortization is as follows:
-------------------------	---

Years ended December 31,	2002	2001	
Reported net income	\$752,736	\$ 222,629	\$ 6
Cumulative effect of change in accounting principle	57,000	-	
Goodwill amortization	-	130,833	1
Adjusted net income before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$809,736	\$ 335,867	\$ 7
Basic earnings per share as reported	\$ 0.26	\$ 0.07	\$
Cumulative effect of change in accounting principle	0.02	-	
Goodwill amortization	-	0.05	
Basic earnings per share before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$ 0.28	\$ 0.12	\$
Diluted earnings per share as reported	\$ 0.26	\$ 0.07	\$
Cumulative effect of change in accounting principle	0.02	-	
Goodwill amortization	-	0.04	
Diluted earnings per share before cumulative effect of change in accounting principle and discontinuance of goodwill amortization	\$ 0.28	\$ 0.11	\$

F-10

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

2. Accounting Policies
(Continued)

Long-Lived Assets

In 2002, the Company adopted Statement of Financial Accounting Standards No 144 ("SFAS 144") "Accounting for the Impairment or Disposal of Long-Lived Assets", which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. Although SFAS 144 supersedes Statement of Financial Accounting Standard No. 121 ("SFAS 121"), "Accounting for the

Impairment of Long-Lived Assets To Be Disposed Of", it retains many of the fundamental provisions of SFAS 121. SFAS 144 also supersedes the accounting and reporting provisions of Accounting Principles Board Opinion No. 30 ("APB 30"), "Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions" for the disposal of a segment of a business. However, it retains the requirement of APB 30 to report separately discontinued operations and extends that reporting to a component of an entity that either has been disposed of, by sale, abandonment, or in a distribution to owners, or is classified as held for sale. The adoption of SFAS 144 did not have a material effect on the Company's consolidated financial statements.

Included in cost of sales for 2002 is an impairment charge of \$50,923 related to machine parts which were used in the electrode assembly machine leasing business. The parts were determined to have no future utilization.

Income Taxes

The Company accounts for income taxes in accordance with SFAS No. 109, "Accounting for Income Taxes," which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

Earnings Per Share Data

The Company follows the provisions of SFAS No. 128 "Earnings Per Share", which requires the Company to present its basic earnings per share and diluted earnings per share, and certain other earnings per share disclosures for each year presented. Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings per share is similar to the computation of basic earnings per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in income or loss that would result from the assumed conversions of those potential shares.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

and Subsidiary
Notes to Consolidated Financial Statements

2. Accounting Policies
(Continued)

Earnings Per
Share Data
(Continued)

Basic and diluted EPS computation for the years
ended December 31, 2002, 2001 and 2000 are as
follows:

Years ended December 31,	2002	
=====		
Net income available to common shareholders	\$ 752,736	\$ 222
Weighted average common shares outstanding	2,875,244	3,009
Basic EPS	\$.26	\$
Diluted EPS:		
Net income available to common shareholders	\$ 752,736	\$ 222
Weighted average common share outstanding	2,875,244	3,009
Assumed conversion of net common shares issuable under stock option plans	60,040	146
Weighted average common and common equivalent shares outstanding	2,935,284	3,156
Diluted EPS	\$.26	\$

The following table summarizes securities
that were outstanding but not included in
the calculation of diluted earnings per
share because their effect would have been
anti-dilutive:

December 31,	2002	
=====		
Stock options	2,000	4

F-12

2. Accounting Policies
(Continued)

Stock-Based
Compensation

The Company accounts for stock options at intrinsic value in accordance with Accounting principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," ("APB 25") and related interpretations. Had compensation cost for the Company's stock options been determined based upon the fair value at the grant date for awards under the plans consistent with the methodology prescribed under Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," the Company's net income would have been adjusted to the pro forma amounts indicated below:

Years ended December 31,	2002	2001
Net income - as reported	\$ 752,736	\$222,600
Deduct: Total stock-based compensation expense determined under fair value based method	(7,876)	
Net income - pro forma	\$ 744,860	\$222,600
Basic earnings per share:		
as reported	\$ 0.26	\$ 0.26
proforma	\$ 0.26	\$ 0.26
Diluted earnings per share:		
as reported	\$ 0.26	\$ 0.26
proforma	\$ 0.25	\$ 0.25

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Fair Value of
Financial
Instruments

The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term maturity of such instruments.

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

2. Accounting Policies

Comprehensive Income (Continued)	The Company follows the provisions of Statement of Financial Accounting Standards No. 130, "Reporting Comprehensive Income", ("SFAS No. 130") which establishes standards for reporting and display of comprehensive income, its components, and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, SFAS No. 130 stipulates that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The Company did not have any components of comprehensive income, exclusive of net income, for the years ended December 31, 2002, 2001 and 2000.
Industry Segments	The Company follows the provisions of Statement of Financial Accounting Standards No. 131, "Disclosure about Segments of an Enterprise and Related Information" ("SFAS No. 131") which requires reporting of selected information about operating segments in interim financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas, and major customers. SFAS No. 131 defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
Shipping and Handling Costs	Shipping and handling costs include primarily freight and are classified as a cost of sales in the consolidated statements of income.
Derivative Instruments	The Company follows the provisions of Statement of Financial Accounting Standards No. 133, "Accounting for Derivatives Instruments and Hedging Activities" ("SFAS No. 133") which requires companies to recognize all derivative contracts as either assets or liabilities in the balance sheet and to measure them at fair value. If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged assets or liability or (ii) the earnings effect of the hedged forecasted transaction. For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change.

The Company has not entered into derivative contracts either to hedge existing risks or for speculative purposes.

Recently Issued
Accounting Standard

In June 2002, The Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 146 ("SFAS 146"), "Accounting for Costs Associated with Exit or Disposal Activities" which addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force ("EITF") Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (including Certain Costs Incurred in a Restructuring)." SFAS 146 is effective for exit or disposal activities initiated after December 31, 2002. The adoption of SFAS 146 is not expected to have a material effect on the Company's consolidated financial statements.

F-14

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

2. Accounting Policies
(Continued)
Recently Issued
Accounting Standard
(continured)

In December 2002, The Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 148 ("SFAS 148"), "Accounting for Stock-Based Compensation - Transition and Disclosure" which amends Statement of Financial Accounting Standard No. 123, "Accounting for Stock-Based Compensation," to provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. It also amends the disclosure provisions of that Statement to require prominent disclosure about the effect on reported net income of an entity's accounting policy decisions with respect to stock-based employee compensation. Finally, this Statement amends Accounting Principles Board Opinion No. 28, "Interim Financial Reporting," to require disclosure about those effects in interim financial information. The Company plan to continue accounting for stock based compensation under the intrinsic value method in accordance with APB 25.

3. Inventories

Inventories consist of the following:

December 31,

2002

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Raw materials	\$ 215,552
Work-in-process	290,368
Finished goods	618,145

Total	\$ 1,124,065
=====	

4. Property, Plant and Equipment

Property, plant and equipment consist of the following:

December 31,	Asset Lives	2002
=====		
Machinery and equipment	5 to 15 years	\$ 4,739,594
Equipment held for lease	10 years	292,621
Building and improvements	20 years	1,869,894
Vehicles	3 to 5 years	24,445
Furniture and fixtures	3 to 5 years	313,378

		7,239,932
Less accumulated depreciation		(4,408,096)

Net property, plant and equipment		\$ 2,831,836
		=====

Equipment
Leasing

The Company leases attaching machines to customers under operating leases for periods of up to one year with renewable terms. The cost of the leased equipment is depreciated on a straight-line basis over ten years. Accumulated depreciation on leased equipment was \$143,920 and \$129,758 at December 31, 2002 and 2001.

F-15

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

5. Debt

Revolving Credit
Facility

The Company has available \$1,000,000 from a revolving credit facility with a bank, which is renewable in May 2003. The agreement provides for borrowings up to 85% of eligible accounts receivable plus 40% of raw material and finished goods inventories. There were no outstanding borrowings on the working capital line of credit as of December 31, 2002 and 2001 and no borrowings during 2002 and 2001. Interest expense includes an unutilized borrowing base charge of \$10,000 in 2002 and 2001.

The agreement contains covenants that, among

various matters, restrict further borrowings and security interests, merger or consolidation, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, changes in ownership and payment of dividends.

Long-Term Debt

Long-term borrowings consist of:

December 31,	2002	2001
=====		
Bonds payable	\$ -	\$ 113,028
Less current maturities	-	113,028

Long-term bonds payable	\$ -	\$ -
=====		

Bonds Payable

In 2000, the Company renewed \$550,000 of a private bond placement for a two-year period maturing May 31, 2002. New warrants were issued to the bondholders for 254,980 shares of the Company's stock at \$1.50 per share. The warrants expired May 31, 2002. The fair-value allocated to the warrants was \$194,000 which was reported as additional paid-in capital and a discount on the debt securities being amortized to interest expense over the two year term of the bonds.

In 2001, the Company redeemed bonds with a face value of \$425,000 and re-purchased the 197,030 associated warrants for \$197,030. In May 2002, the matured bonds were paid in full and the remaining 57,950 warrants were exercised.

For the years 2002, 2001 and 2000, the Company recorded amortization of bond discount of \$11,972, \$138,538 and \$63,490, respectively and interest expense of \$5,729, \$48,055 and \$63,250 in 2002, 2001 and 2000.

F-16

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

6. Income Taxes

The income tax provision for each of the three years in the period ended December 31, 2002 consists of the following:

	2002	2001
=====		
Current:		
Federal	\$ -	\$ -

State	52,000	10,0

	52,000	10,0
Deferred	-	

Total income tax provision	\$52,000	\$10,0
=====		

The Company's federal net operating loss ("NOL") carryforwards were approximately \$1,300,000 at December 31, 2002 and expire through 2007. The use of the loss carryforwards to reduce future income tax obligations are limited in any given year due to restrictions defined in the Internal Revenue Code related to a change in ownership control.

The components of deferred income taxes were as follows as of December 31:

	20
=====	
Deferred income taxes:	
Inventories	\$ 46,0
Property, plant and equipment	43,0
Patents	199,0
Other	83,9
Net operating loss carryforwards	442,0
Valuation allowance	(369,0)

Deferred income taxes	\$ 444,9
=====	

Deferred tax assets are recognized by reducing the valuation allowance as the Company generates income, or when, in the opinion of management, significant positive evidence exists that the Company will be more likely than not to realize the tax benefits related to temporary differences which give rise to deferred tax assets.

F-17

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

6. Income Taxes
(Continued)

The Company files a consolidated federal income tax return. For financial statement purposes, the actual effective consolidated tax rates have been applied to the income before income taxes when calculating the tax provision. The actual income

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

tax provision differs from the statutory income tax rate (34%) as follows:

	2002	2001
Tax provision computed at statutory rate	\$ 292,990	\$ 79,000
Increases (reductions) due to:		
Tax effect of change in accounting principle	(25,000)	
Amortization of goodwill	-	39,000
State income taxes net of federal benefit	34,320	6,600
Changes in valuation allowance estimates	(249,446)	(130,700)
Other	(864)	16,000
Income tax expense	\$ 52,000	\$ 10,000

7. Employee Benefit Plans

The Company sponsors an Employee Savings and Investment Plan under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. Employees can contribute up to 90% of their eligible compensation or up to the maximum allowable by the IRS. The Company's matching contributions are at the discretion of management. The Company did not make any contributions for the years ended December 31, 2002, 2001 and 2000.

8. Commitments and Contingencies

Royalties

ART licenses its signal-averaging technology from an unrelated entity for a royalty fee of 4.5% of gross sales, less certain allowances for selling commissions and discounts. Costs of obtaining patents are offset against royalties due. To retain an exclusive license for the technology, ART is obligated to pay a minimum royalty of \$30,000 annually. The royalties paid were \$3,917, \$30,000 and \$30,000 for each of 2002, 2001 and 2000, respectively. The license expired in February 2002.

Electrophysiology Products Contract

ART and Prucka Engineering, Inc. ("Prucka"), the manufacturer of the CardioLab and CardioMapp products (the "Products") had an agreement related to ART's distribution of the Products. The agreement provided for ART to receive a 3% commission on CardioLab sales through December 31, 2002. In 2000, Prucka (now owned by GE/Marquette) negotiated to buy out the remainder of the commission agreement for \$1,000,000 with no further obligations to either party.

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

8. Commitments and
Contingencies
(Continued)

Environmental
Groundwater

Like many industrial processes, the Micron manufacturing process utilizes hazardous and non-hazardous chemicals, the treatment and disposal of which are subject to federal and state regulation. Since its inception, Micron has expended significant funds to train its personnel, install waste treatment and recovery equipment and to retain an independent environmental consulting firm to constantly review, monitor and upgrade its air and waste water treatment activities. As a result, Micron believes that the operations of its manufacturing facility are in compliance with currently applicable safety, health and environmental laws and regulations.

Based on the Company's analyses and subject to the difficulty in estimating these future costs, the Company does not expect future costs in connection with environmental matters to have a material adverse effect on financial condition, result of operations or liquidity.

Employment
Agreement

The Company has an employment agreement with a certain executive extending through September 2006. The agreement provide for a base compensation and certain other benefits. The agreement also contains other terms and conditions of employment, including termination payments under certain circumstances.

Operating Leases

The Company leases vehicles and equipment under non-cancelable lease arrangements. Lease expense under all operating leases was approximately \$40,000, \$77,000 and \$117,000 in 2002, 2001 and 2000, respectively.

Future minimum operating lease payments as of December 31, 2002 are approximately as follows:

Year	Amount
=====	
2003	\$32,000
2004	26,000
2005	15,000

Total	\$73,000
=====	

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

9. Supplemental
Cash Flow
Information

Cash paid for income taxes and interest for the years ended December 31 are as follows:

	2002	2001
Income taxes	\$15,000	\$13,185
Interest	\$10,203	\$78,428
Non-cash activities:		
Bond discount resulting from bond and stock warrant renewal	\$ -	\$ -
Directors fees paid in stock	\$ -	\$ -

10. Related Party
Transactions

The Company obtains legal services with respect to its patents from a law firm, a partner of which is a shareholder and Director of the Company. Fees for services and patent prosecution costs paid to this firm were approximately \$18,600, \$25,000 and \$37,700 for years 2002, 2001 and 2000, respectively. The amounts owed to this firm at December 31, 2002 and 2001 were approximately \$0 and \$6,000, respectively.

Cardio Digital Inc. ("CDI") has four shareholders who are also shareholders of the Company. Royalties paid CDI were \$0, \$450 and \$6,100 for years 2002, 2001 and 2000, respectively.

During the years 2002, 2001 and 2000 healthcare coverage premiums of approximately \$7,400, \$7,800 and \$11,670, respectively, were paid on behalf of a Director of the Company in exchange for consulting services.

The Company obtains consulting services from a shareholder and Director of the Company related to acquisitions and other negotiations. Fees paid to this Director during the years 2002, 2001 and 2000 were \$5,250, \$8,048 and \$0, respectively.

F-20

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

11. Stock Options

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

2001 Stock
Option Plan

In October 2001, the shareholders approved the adoption of the 2001 Stock Option Plan (the "Option Plan") and reserved 200,000 shares of the Company's common stock for issuance under the new Option Plan. Under the Option Plan, options become exercisable commencing one year from the date of grant at the rate of 20% of the amount granted per year and expire six years from the date of grant. The exercise price is the fair market value of the common stock on the date of the grant.

In 2001, options for 60,000 shares were granted to two officers at an exercise price of \$2.00. After the resignation of one of those officers, 6,000 of the options were exercisable at December 31, 2002 and 170,000 are available for future grants. The weighted average fair market value on the date of grant of the options granted was \$1.31.

The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The model uses assumptions for dividend yield, expected volatility, and the risk-free interest rate.

The assumptions used for the 60,000 options issued in 2001 were a dividend yield of 0%, expected volatility of .8, and a risk free rate of 3.0%.

Incentive Stock
Option Plan

The Company had reserved 250,000 shares of its common stock for issuance to officers and Option Plan key employees pursuant to an Incentive Stock Option Plan (the "ISO Plan"). Under the ISO Plan, options become exercisable commencing one year from the date of grant at the rate of 20% of the total granted per year and expire ten years from the date of grant. The exercise price is the fair market value of the common stock on the date of grant. The range of exercise prices was \$1.06 to \$6.00 per share for all options outstanding and granted under the ISO Plan with a weighted average exercise price of \$1.44 per share and weighted average remaining life of 2.4 years. The ISO Plan was terminated for additional grants in 2001.

F-21

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

11. Stock Options
(Continued)

Incentive Stock

Transactions under the ISO Plan are summarized as

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

Option Plan

follows:

	2002	2001
Options outstanding at beginning of year	28,000	51,000
Exercised	-	(8,000)
Cancelled/expired	(2,000)	(15,000)
Options outstanding at end of year	26,000	28,000
Options exercised to date	12,500	12,500
Available for grant at end of year	-	-
Exercisable at end of year	26,000	28,000

Non-Plan Options

During 1994, non-plan options for 144,000 shares, expiring in 2004, at an exercise price of \$3.00, were granted to eight Directors. During September 1998, the Board of Directors repriced options outstanding to Directors and Officers. All options were repriced to reflect the fair market value on the effective date of \$1.06 per share. During 2002, the remaining 72,000 options were exercised.

Transactions relative to non-plan options are summarized as follows:

	2002	2001
Options outstanding at beginning of year	72,000	90,000
Exercised	(72,000)	(18,000)
Cancelled/expired	-	-
Options outstanding at end of year	-	72,000
Exercisable at end of year	-	72,000

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

12. Industry and Geographic Segments The Company's operations are classified into two business segments: medical electrode components and computerized medical instruments.

The following table shows sales, operating income (loss) and other financial information by industry segment as of and for the years ended December 31, 2002, 2001 and 2000:

	Medical Electrode Components	Computerized Medical Instruments	Corpora
Year ended December 31, 2002			
Sales	\$7,188,325	\$ 3,740	\$
Operating income (loss)	\$ 927,099	\$ (64,446)	\$
Capital Expenditures	\$ 219,325	\$ -	\$
Depreciation and Amortization Identifiable assets at December 31, 2002	\$ 609,158	\$ -	\$ 11,
	\$5,411,611	\$ 15,106	\$3,051,

	Medical Electrode Components	Computerized Medical Instruments	Corpora
Year ended December 31, 2001			
Sales	\$7,077,951	\$ 141,737	\$
Operating income (loss)	\$ 838,239	\$ (402,580)	\$ (130,
Capital Expenditures	\$ 675,111	\$ -	\$
Depreciation and Amortization Identifiable assets at December 31, 2001	\$ 725,678	\$ 3,463	\$ 301,
	\$5,395,525	\$ 17,248	\$3,270,

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

12. Industry and
Geographic
Segments
(Continued)

	Medical Electrode Components	Computerized Medical Instruments	Corporate

Year ended December 31, 2000			
Sales	\$8,407,040	\$ 1,114,823 (A)	\$ -

Operating income (loss)	\$ 589,402	\$ 353,144	\$ (129,889)

Capital Expenditures	\$ 246,658	\$ -	\$ -
Depreciation and Amortization	\$ 777,576	\$ 12,778	\$ 258,264
Identifiable assets at December 31, 2000	\$6,079,844	\$ 227,819	\$3,610,921

(A) Includes a \$1,000,000 buyout and termination of GE/Prucka commission agreement.

The following table sets forth the geographic distribution of t

	2002	2001

Canada	\$ 3,133,890	\$ 2,765,000
Europe	1,239,172	1,421,000
United Kingdom	1,430,459	1,397,000
United States	1,115,941	1,311,000
Other	272,603	323,000

Net Sales	\$ 7,192,065	\$ 7,219,000

(A) Includes a \$1,000,000 buyout and termination of GE/Prucka c

Arrhythmia Research Technology, Inc.
and Subsidiary
Notes to Consolidated Financial Statements

12. Industry and Geographic Segments (Continued) The following table sets forth the percentage of net sales to significant customers of the medical electrode components segment in relation to total segment sales:

Customers	2002	2001
A	36%	38%
B	19%	18%
C	20%	22%

The single significant customer for the computerized medical instruments segment was revenue from the GE/Prucka commission agreement, which was terminated in 2000. For the year ended December 31, 2000, this was 90% of computerized medical instrument net sales, respectively.

13. Quarterly Financial Data

	First Quarter	Second Quarter	Third Quarter
2002			
Net sales	\$ 1,915,097	\$ 1,832,237	\$1,630,427
Gross profit	632,381	577,180	548,463
Net income	145,021	101,440	178,744
Earnings per share	0.05	0.03	0.06
2001			
Net sales	\$ 1,753,974	\$ 1,874,662	\$1,637,050
Gross profit	504,507	634,667	456,152
Net income	34,052	102,652	80,766
Earnings per share	0.01	0.03	0.03

During the fourth quarter of 2002, the Company determined that \$50,923 of electrode assembly machine parts had no future value and were charged to expense. Also in the fourth quarter of 2002, the Company adjusted income tax expense by approximately \$80,000 to better reflect the expected utilization of deferred tax assets.

Arrhythmia Research Technology, Inc.
and Subsidiary
Schedule II

REPORT OF INDEPENDENT ACCOUNTANTS ON SCHEDULE

To the Shareholders
Arrhythmia Research Technology, Inc.

The audits referred to in our report dated February 14, 2003 relating to the consolidated financial statements of Arrhythmia Research Technology, Inc. and Subsidiary, which is contained in Item 8 of this form 10-K included the audits of the financial statement schedule for the years ended December 31, 2002, 2001 and 2000 listed in Item 14 (a) (2). This financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on this financial statement schedule based on our audits.

In our opinion such financial statement schedule presents fairly, in all material respects, the information set forth therein for the years ended December 31, 2002, 2001 and 2000.

/s/ BDO Seidman, LLP
Gardner, Massachusetts
February 14, 2003

F-26

Arrhythmia Research Technology, Inc.
And Subsidiary
Schedule II
Valuation and Qualifying Accounts

	Balance at Beginning of Year	Charged to Costs and Expenses	Deductions	Bal at of
=====				
Allowance for doubtful accounts:				
2002	\$ 51,000	\$ -	\$ 12,000	\$ 39
=====				
2001	\$ 52,827	\$ 35,978	\$ 37,805	\$ 51
=====				
2000	\$ 83,203	\$ 56,918	\$ 87,294	\$ 52
=====				
Allowance for slow-moving inventories:				
=====				
2002	\$ 111,654	\$ -	\$ 6,315	\$ 105

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-K

2001	\$ 150,487	\$ -	\$ 38,833	\$ 111
2000	\$ 458,500	\$ 24,433	\$332,446	\$ 150